Remove 2028 Remove Pharma Remove Physicians
article thumbnail

US Healthcare Industry Sectors: Facts, Trends, & Statistics

Medico Reach

trillion by 2028. The healthcare industry is currently undergoing a paradigm shift, and with a technology-enabled healthcare model in place, the role of general physicians will change forever. billion Pharma: $169.9 The industry was worth around 19.7% of the US GDP in 2020. The US national healthcare expenditure for 2020 was $4.1

article thumbnail

An increasing impact of BCMA-targeting biologics in multiple myeloma

Pharmaceutical Technology

Since the frontline treatment setting is dominated by these regimens, pharma companies have focused on the development of new drugs in the relapsed/refractory (R/R) setting. However, the lack of mature overall survival data for either agent means physicians will have to select therapy based on attributes other than long-term efficacy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

article thumbnail

Making Sense of the Latest Changes to the Market Access Landscape

PM360

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

article thumbnail

Reaching for the gold standard of lung cancer screening

pharmaphorum

As part of efforts to increase uptake of screening programmes, purpose-driven partnerships between the NHS and the pharma industry have emerged as an innovative solution to raise patient awareness. The goal set out by the NHSE Long Term Plan is ambitions: to have three quarters of cancers diagnosed at an early stage by 2028.

article thumbnail

An app can never replace a doctor

World of DTC Marketing

Together with the growth in wearables—projected to be worth nearly $120 billion by 2028—we are seeing growing democratization of knowledge of one’s own body, with tech enabling consumers to take a more active and regular role in their healthcare. Physicians have not bought into the hype around apps. The Economist.

Doctors 208
article thumbnail

CMS enters drug price negotiation arena in sea change for industry

Clarivate

In 2026, CMS will select up to 15 additional Part B or Part D drugs for negotiations that take effect in 2028, and up to 20 additional drugs every year thereafter (Part B covers physician-administered drugs, including infusions of complex biologics).